title: Genomic landscape of intracranial meningiomas.
abstract: Meningiomas are the most common primary intracranial neoplasms in adults. Current histopathological grading schemes do not consistently predict their natural history. Classic cytogenetic studies have disclosed a progressive course of chromosomal aberrations, especially in high-grade meningiomas. Furthermore, the recent application of unbiased next-generation sequencing approaches has implicated several novel genes whose mutations underlie a substantial percentage of meningiomas. These insights may serve to craft a molecular taxonomy for meningiomas and highlight putative therapeutic targets in a new era of rational biology-informed precision medicine.
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital;|Department of Cancer Biology, Dana-Farber Cancer Institute; and.
authors.forename: Wenya Linda
authors.initials: WL
authors.lastname: Bi
authors.affiliation: Department of Pathology, Division of Neuropathology, Brigham and Women's Hospital.
authors.forename: Malak
authors.initials: M
authors.lastname: Abedalthagafi
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital;
authors.forename: Peleg
authors.initials: P
authors.lastname: Horowitz
authors.affiliation: Department of Neurosurgery, Massachusetts General Hospital;|Department of Cancer Biology, Dana-Farber Cancer Institute; and.
authors.forename: Pankaj K
authors.initials: PK
authors.lastname: Agarwalla
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital;
authors.forename: Yu
authors.initials: Y
authors.lastname: Mei
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and.
authors.forename: Ayal A
authors.initials: AA
authors.lastname: Aizer
authors.affiliation: Department of Pathology, Division of Neuropathology, Brigham and Women's Hospital.
authors.forename: Ryan
authors.initials: R
authors.lastname: Brewster
authors.affiliation: Department of Neurosurgery, Pathology, and Immunology, Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri.
authors.forename: Gavin P
authors.initials: GP
authors.lastname: Dunn
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital;
authors.forename: Ossama
authors.initials: O
authors.lastname: Al-Mefty
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and.
authors.forename: Brian M
authors.initials: BM
authors.lastname: Alexander
authors.affiliation: Department of Pathology, Division of Neuropathology, Brigham and Women's Hospital.
authors.forename: Sandro
authors.initials: S
authors.lastname: Santagata
authors.affiliation: Department of Cancer Biology, Dana-Farber Cancer Institute; and.
authors.forename: Rameen
authors.initials: R
authors.lastname: Beroukhim
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital;
authors.forename: Ian F
authors.initials: IF
authors.lastname: Dunn
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008577:Meningeal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D008579:Meningioma / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D009154:Mutation; D057285:Precision Medicine
keywords: MAPK = mitogen-activated protein kinase; NF2 = neurofibromatosis Type 2; PI3K = phosphoinositide-3-kinase; genomics; hpf = high-power field; mTOR = mammalian target of rapamycin; meningioma; molecular taxonomy; oncology; precision medicine; targeted therapy; tumor classification; tumor progression